{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T20:38:09Z","timestamp":1778531889153,"version":"3.51.4"},"reference-count":26,"publisher":"Informa UK Limited","issue":"6","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Astellas Pharma Inc"},{"DOI":"10.13039\/100020124","name":"Seagen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020124","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncology"],"published-print":{"date-parts":[[2025,3,3]]},"DOI":"10.1080\/14796694.2025.2459058","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T03:06:22Z","timestamp":1740020782000},"page":"665-679","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Epidemiology, resource use, and treatment patterns of locally advanced or metastatic urothelial carcinoma in France"],"prefix":"10.1080","volume":"21","author":[{"given":"Florence","family":"Joly","sequence":"first","affiliation":[{"name":"Normandie University, UNICAEN","place":["Caen, France"]},{"name":"Centre Fran\u00e7ois Baclesse","place":["Caen, France"]},{"name":"CHU de Caen","place":["Caen, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephane","family":"Culine","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint-Louis, AP-HP","place":["Paris, France"]},{"name":"Paris-Diderot University","place":["Paris, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgan","family":"Roupret","sequence":"additional","affiliation":[{"name":"Sorbonne University","place":["Paris, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurore","family":"Tricotel","sequence":"additional","affiliation":[{"name":"IQVIA","place":["La D\u00e9fense Cedex, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Casarotto","sequence":"additional","affiliation":[{"name":"IQVIA","place":["La D\u00e9fense Cedex, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Brice","sequence":"additional","affiliation":[{"name":"IQVIA","place":["La D\u00e9fense Cedex, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Minacori","sequence":"additional","affiliation":[{"name":"Astellas Pharma","place":["Levallois-Perret, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marthe","family":"Vuillet","sequence":"additional","affiliation":[{"name":"Astellas Pharma","place":["Levallois-Perret, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Catherine","family":"Thomas","sequence":"additional","affiliation":[{"name":"Astellas Pharma","place":["Levallois-Perret, France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"Leyland","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe","place":["Addlestone, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anil","family":"Upadhyay","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe","place":["Addlestone, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicki","family":"Munro","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe","place":["Addlestone, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6032-8794","authenticated-orcid":false,"given":"Torsten","family":"Strunz-McKendry","sequence":"additional","affiliation":[{"name":"Astellas Pharma Europe","place":["Addlestone, UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.07.039"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/551S34a"},{"key":"e_1_3_8_5_1","unstructured":"Witjes JA Bruins HM Carri\u00f3n A et al. Muscle-invasive and metastatic bladder cancer [Internet]. Arnhem The Netherlands: European Association of Urology; [cited 2022 Jul 8]. Available from: https:\/\/uroweb.org\/guidelines\/muscle-invasive-and-metastatic-bladder-cancer"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.purol.2022.07.145"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.11.012"},{"issue":"12","key":"e_1_3_8_8_1","first-page":"S78","article-title":"French CCAFU guidelines - update 2020\u20132022: bladder cancer","volume":"30","author":"Roupr\u00eat M","year":"2020","unstructured":"Roupr\u00eat M, Pignot G, Masson-Lecomte A, et al. French CCAFU guidelines - update 2020\u20132022: bladder cancer. Prog Urol. 2020;30(12S):S78\u2013S135.","journal-title":"Prog Urol"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol30040277"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.4565"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/2168479018763591"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyw359"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0221211"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12214"},{"key":"e_1_3_8_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000471"},{"key":"e_1_3_8_16_1","unstructured":"Bilan d\u00e9mographique 2020 [2020 demographic report] [Internet]. Montrouge France: Institut national de la statistique et des \u00e9tudes \u00e9conomiques; 2021 [cited 2022 Jul 8]. Available from: https:\/\/www.insee.fr\/fr\/statistiques\/5007688?sommaire=5007726"},{"key":"e_1_3_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2022.09.2059"},{"key":"e_1_3_8_18_1","unstructured":"KEYTRUDA - Avis de la commission de la Transparence adopt\u00e9 le 21 f\u00e9vrier 2018 [KEYTRUDA - Opinion of the Transparency Commission adopted on February 21 2018] Internet]. Paris France: Haute Autorit\u00e9 de sant\u00e9; 2018 [cited 2020 Nov 20]. French. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/evamed\/CT-16530_KEYTRUDA_carcinome_urothelial_PIC_EI_Avis3_CT16530.pdf"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2023.09.010"},{"key":"e_1_3_8_20_1","volume-title":"Avis sur les m\u00e9dicaments: enfortumab vedotin PADCEV 20 mg et 30 mg, poudre pour solution \u00e0 diluer pour perfusion. Premi\u00e8re \u00e9valuation [Drug reviews: enfortumab vedotin PADCEV 20 mg and 30 mg, powder for solution for dilution for infusion. First assessment]","year":"2022","unstructured":"Avis sur les m\u00e9dicaments: enfortumab vedotin PADCEV 20 mg et 30 mg, poudre pour solution \u00e0 diluer pour perfusion. Premi\u00e8re \u00e9valuation [Drug reviews: enfortumab vedotin PADCEV 20 mg and 30 mg, powder for solution for dilution for infusion. First assessment]. French. Paris, France: Haute Autorit\u00e9 de sant\u00e9; 2022 Dec 7. https:\/\/www.has-sante.fr\/upload\/docs\/evamed\/CT-19842_PADCEV_PIC_INS_AvisDef_CT19842.pdf"},{"key":"e_1_3_8_21_1","unstructured":"D\u00e9cision n\u00b0 2022.0467\/DC\/SEM du 8 d\u00e9cembre 2022 du coll\u00e8ge de la Haute Autorit\u00e9 de sant\u00e9 portant renouvellement de l\u2019autorisation d\u2019acc\u00e8s pr\u00e9coce de la sp\u00e9cialit\u00e9 PADCEV [Decision No. 2022.0467\/DC\/SEM of December 8 2022 of the college of the Haute Autorit\u00e9 de sant\u00e9 renewing the authorization for early access to the PADCEV specialty] [Internet]. Paris France: Haute Autorit\u00e9 de sant\u00e9; 2022 [cited 2023 Mar 15]. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2022-12\/padcev_ap136_decision_et_avisct_renouvellement_aa.pdf"},{"key":"e_1_3_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.106"},{"key":"e_1_3_8_23_1","unstructured":"European Commission approves Astellas\u2019. PADCEVTM (enfortumab vedotin) in combination with KEYTRUDA\u00ae (pembrolizumab) for first-line treatment of advanced urothelial cancer [Internet]. Tokyo Japan: Astellas Pharma Inc; 2024 Aug 28 [cited 2024 Sep 11]. Available from: https:\/\/www.astellas.com\/en\/news\/29371"},{"key":"e_1_3_8_24_1","volume-title":"Enfortumab vedotin PADCEV 20 mg et 30 mg, poudre pour solution \u00e0 diluer pour perfusion. Acc\u00e8s pr\u00e9coce post-AMM [Drug reviews: Enfortumab vedotin PADCEV 20 mg and 30 mg, powder for solution for dilution for infusion. Early access post-marketing authorization]","author":"Avis sur les m\u00e9dicaments","year":"2024","unstructured":"Avis sur les m\u00e9dicaments. Enfortumab vedotin PADCEV 20 mg et 30 mg, poudre pour solution \u00e0 diluer pour perfusion. Acc\u00e8s pr\u00e9coce post-AMM [Drug reviews: Enfortumab vedotin PADCEV 20 mg and 30 mg, powder for solution for dilution for infusion. Early access post-marketing authorization]. French. Paris, France: Haute Autorit\u00e9 de sant\u00e9; 2024 Sep 4. https:\/\/ansm.sante.fr\/tableau-acces-derogatoire\/impression\/317"},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.10.024"},{"key":"e_1_3_8_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12904-018-0327-z"},{"key":"e_1_3_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4758"},{"key":"e_1_3_8_28_1","unstructured":"KEYTRUDA avis d\u2019efficience carcinome uroth\u00e9lial (2\u00e8me ligne) [Internet]. Paris France: Haute Autorit\u00e9 de Sant\u00e9; 2018 [cited 2023 Sep 28]. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2018-10\/keytruda_10072018_avis_efficience.pdf"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14796694.2025.2459058","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T07:52:40Z","timestamp":1769586760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14796694.2025.2459058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,3,3]]}},"alternative-id":["10.1080\/14796694.2025.2459058"],"URL":"https:\/\/doi.org\/10.1080\/14796694.2025.2459058","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-04-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}